Capricor Therapeutics, Inc. · Brief

Next report

8 days

Nov 9 · after closeest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

2 of 8≥ implied

Nov 13 '24±12.3%▲+9.34%×0.76

Mar 19 '25±8.2%▲+17.51%×2.13

May 13 '25±10.1%▲+5.07%×0.50

Aug 11 '25±18.5%▲+2.88%×0.16

Q3 FY25±50.7%▲+11.51%×0.23

Q1 FY26±10.0%▼−8.74%×0.87

May 12 '26±9.0%▼−3.78%×0.42

Q2 FY26±35.1%▲+57.96%×1.65

quarterimplied−60%0+60%realized×

Q2 FY26±35.1%▲+57.96%×1.65

May '26±9.0%▼−3.78%×0.42

Q1 FY26±10.0%▼−8.74%×0.87

Q3 FY25±50.7%▲+11.51%×0.23

Aug '25±18.5%▲+2.88%×0.16

May '25±10.1%▲+5.07%×0.50

2 older reports

Mar '25±8.2%▲+17.51%×2.13

Nov '24±12.3%▲+9.34%×0.76

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 9 report · est.

Bull2 of 4

+24.18%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

175managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

4tracked funds holding CAPRN-PORT · Aug 31 '26

0.49%share of State Street SPDR S&P Biotech ETF assets as the largest fund weightN-PORT · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

CAPR report session

No linked exposure.

Oct 26impliedImplied move: ±51.5% into Nov 9 earnings (Oct 26 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.